Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension (Advances in Therapy, (2018), 35, 6, (796-808), 10.1007/s12325-018-0718-9)

Suzuki K., Otsuka N., Hizaki H., Hashimoto M., Kuwayama Y., On behalf of the Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group

2019
Advances in Therapy

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Suzuki Eye Clinic, Yamaguchi, Japan; Santen Pharmaceutical Co., Ltd., Osaka, Japan; Fukushima Eye Clinic, Osaka, Japan

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications